Click here to close now.




















Welcome!

News Feed Item

Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014

LONDON, April 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/research_rd/clinical_trials/non_small_cell_lung_cancer_global_clinical_trials_review.html

Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014" provides data on the Non-Small Cell Lung Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Small Cell Lung Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Small Cell Lung Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Introduction 6
Non-Small Cell Lung Cancer 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Non-Small Cell Lung Cancer 25
Subjects Recruited Over a Period of Time 57
Clinical Trials by Sponsor Type 58
Prominent Sponsors 59
Top Companies Participating in Non-Small Cell Lung Cancer Therapeutics Clinical Trials 60
Prominent Drugs 62

Latest Clinical Trials News on Non-Small Cell Lung Cancer 63
Mar 02, 2014: Genentech Provides Update on Phase III Study of Onartuzumab in People with Specific Type of Lung Cancer 63
Feb 19, 2014: Lilly Announces Ramucirumab Phase III Lung Cancer Trial Meets Primary Endpoint of Overall Survival 63
Feb 17, 2014: Afatinib: added benefit depends on mutation status 64
Jan 27, 2014: Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer 65
Jan 16, 2014: ArQule Provides Updates on Clinical Trials in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer with Tivantinib 66
Clinical Trial Profiles 68
Clinical Trial Overview of Top Companies 68
F. Hoffmann-La Roche Ltd. 68
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 68
Eli Lilly and Company 84
Clinical Trial Overview of Eli Lilly and Company 84
AstraZeneca PLC 98
Clinical Trial Overview of AstraZeneca PLC 98
Pfizer Inc. 109
Clinical Trial Overview of Pfizer Inc. 109
Bristol-Myers Squibb Company 117

Clinical Trial Overview of Bristol-Myers Squibb Company 117
Sanofi 123
Clinical Trial Overview of Sanofi 123
Novartis AG 128
Clinical Trial Overview of Novartis AG 128
Merck & Co., Inc. 133
Clinical Trial Overview of Merck & Co., Inc. 133
GlaxoSmithKline plc 137
Clinical Trial Overview of GlaxoSmithKline plc 137
C. H. Boehringer Sohn AG & Co. KG 141
Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG 141
Clinical Trial Overview of Top Institutes / Government 145
National Cancer Institute 145
Clinical Trial Overview of National Cancer Institute 145
The University of Texas M. D. Anderson Cancer Center 168
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 168
Memorial Sloan Kettering Cancer Center 172
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 172
West Japan Oncology Group 176
Clinical Trial Overview of West Japan Oncology Group 176
European Organization for Research and Treatment of Cancer 179
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 179
Radiation Therapy Oncology Group 182
Clinical Trial Overview of Radiation Therapy Oncology Group 182
Sun Yat-sen University 184
Clinical Trial Overview of Sun Yat-sen University 184

Eastern Cooperative Oncology Group 186
Clinical Trial Overview of Eastern Cooperative Oncology Group 186
Sarah Cannon Research Institute 188
Clinical Trial Overview of Sarah Cannon Research Institute 188
Barbara Ann Karmanos Cancer Institute 190
Clinical Trial Overview of Barbara Ann Karmanos Cancer Institute 190
Five Key Clinical Profiles 192
Appendix 292
Abbreviations 292
Definitions 292
Research Methodology 293
Secondary Research 293
About GlobalData 294
Contact Us 294
Disclaimer 294
Source 295

List of Tables

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region, 2014* 7
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase, 2014* 21

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Non-Small Cell Lung Cancer Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Non-Small Cell Lung Cancer Therapeutics, Global, Withdrawn Clinical Trials, 2014* 28
Non-Small Cell Lung Cancer Therapeutics, Global, Terminated Clinical Trials, 2014* 33
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 57
Non-Small Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 58
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 59
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 61
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 62
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 68
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 84
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 98

Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 109
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 117
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 123
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 128
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 133
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 137
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG & Co. KG, 2014* 141
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 145
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 168
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 172

Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by West Japan Oncology Group, 2014* 176
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 179
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Radiation Therapy Oncology Group, 2014* 182
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sun Yat-sen University, 2014* 184
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eastern Cooperative Oncology Group, 2014* 186
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sarah Cannon Research Institute, 2014* 188
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Barbara Ann Karmanos Cancer Institute, 2014* 190

List of Figures
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17

Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 57
Non-Small Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 58
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 59
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 60
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 62
GlobalData Methodology 293

Read the full report:
Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/research_rd/clinical_trials/non_small_cell_lung_cancer_global_clinical_trials_review.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
How do you securely enable access to your applications in AWS without exposing any attack surfaces? The answer is usually very complicated because application environments morph over time in response to growing requirements from your employee base, your partners and your customers. In his session at @DevOpsSummit, Haseeb Budhani, CEO and Co-founder of Soha, shared five common approaches that DevOps teams follow to secure access to applications deployed in AWS, Azure, etc., and the friction an...
"Alert Logic is a managed security service provider that basically deploys technologies, but we support those technologies with the people and process behind it," stated Stephen Coty, Chief Security Evangelist at Alert Logic, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Digital Transformation is the ultimate goal of cloud computing and related initiatives. The phrase is certainly not a precise one, and as subject to hand-waving and distortion as any high-falutin' terminology in the world of information technology. Yet it is an excellent choice of words to describe what enterprise IT—and by extension, organizations in general—should be working to achieve. Digital Transformation means: handling all the data types being found and created in the organizat...
The Internet of Everything (IoE) brings together people, process, data and things to make networked connections more relevant and valuable than ever before – transforming information into knowledge and knowledge into wisdom. IoE creates new capabilities, richer experiences, and unprecedented opportunities to improve business and government operations, decision making and mission support capabilities.
The essence of cloud computing is that all consumable IT resources are delivered as services. In his session at 15th Cloud Expo, Yung Chou, Technology Evangelist at Microsoft, demonstrated the concepts and implementations of two important cloud computing deliveries: Infrastructure as a Service (IaaS) and Platform as a Service (PaaS). He discussed from business and technical viewpoints what exactly they are, why we care, how they are different and in what ways, and the strategies for IT to tran...
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin,...
The Internet of Things is not only adding billions of sensors and billions of terabytes to the Internet. It is also forcing a fundamental change in the way we envision Information Technology. For the first time, more data is being created by devices at the edge of the Internet rather than from centralized systems. What does this mean for today's IT professional? In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists addressed this very serious issue of pro...
With SaaS use rampant across organizations, how can IT departments track company data and maintain security? More and more departments are commissioning their own solutions and bypassing IT. A cloud environment is amorphous and powerful, allowing you to set up solutions for all of your user needs: document sharing and collaboration, mobile access, e-mail, even industry-specific applications. In his session at 16th Cloud Expo, Shawn Mills, President and a founder of Green House Data, discussed h...
Container technology is sending shock waves through the world of cloud computing. Heralded as the 'next big thing,' containers provide software owners a consistent way to package their software and dependencies while infrastructure operators benefit from a standard way to deploy and run them. Containers present new challenges for tracking usage due to their dynamic nature. They can also be deployed to bare metal, virtual machines and various cloud platforms. How do software owners track the usag...
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
Discussions about cloud computing are evolving into discussions about enterprise IT in general. As enterprises increasingly migrate toward their own unique clouds, new issues such as the use of containers and microservices emerge to keep things interesting. In this Power Panel at 16th Cloud Expo, moderated by Conference Chair Roger Strukhoff, panelists addressed the state of cloud computing today, and what enterprise IT professionals need to know about how the latest topics and trends affect t...
"Our biggest growth area has been the security services, the managed services - the things that differentiate us in the market that there is no client that's too small and there's no client that's too big," explained Paul Mazzucco, Chief Security Officer at TierPoint, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
Countless business models have spawned from the IaaS industry. Resell Web hosting, blogs, public cloud, and on and on. With the overwhelming amount of tools available to us, it's sometimes easy to overlook that many of them are just new skins of resources we've had for a long time. In his General Session at 16th Cloud Expo, Phil Jackson, Lead Technology Evangelist at SoftLayer, broke down what we've got to work with and discuss the benefits and pitfalls to discover how we can best use them to d...
Containers are changing the security landscape for software development and deployment. As with any security solutions, security approaches that work for developers, operations personnel and security professionals is a requirement. In his session at DevOps Summit, Kevin Gilpin, CTO and Co-Founder of Conjur, will discuss various security considerations for container-based infrastructure and related DevOps workflows.